Billeter Marianne, Zervos Marcus J, Chen Anne Y, Dalovisio Joseph R, Kurukularatne Changa
Department of Infectious Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA.
Clin Infect Dis. 2008 Feb 15;46(4):577-83. doi: 10.1086/526772.
The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection. Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extremely long half-life, permitting once-weekly intravenous dosing. Clinical studies comparing linezolid with 2 doses of dalbavancin have shown comparable efficacy for the treatment of skin and soft-tissue infection. Dalbavancin has also proven to be effective for therapy of catheter-related bloodstream infections. It has an excellent safety profile in studies to date. Dalbavancin will likely have a significant role in outpatient intravenous therapy for patients with potentially serious drug-resistant gram-positive coccal infections.
耐甲氧西林金黄色葡萄球菌等耐药革兰氏阳性球菌的患病率不断上升，凸显了治疗此类感染所需新药物的必要性。达巴万星是一种新型脂糖肽，与万古霉素相比，它对大多数革兰氏阳性病原菌具有体外活性增强的理想特性，且半衰期极长，允许每周一次静脉给药。比较利奈唑胺与两剂达巴万星的临床研究表明，二者在治疗皮肤和软组织感染方面疗效相当。达巴万星也已被证明对导管相关血流感染的治疗有效。迄今为止，它在研究中具有出色的安全性。对于患有潜在严重耐药革兰氏阳性球菌感染的患者，达巴万星可能在门诊静脉治疗中发挥重要作用。
